|本期目录/Table of Contents|

[1]张和倩,常文仙,焦艳梅,等.HIV 病毒库清除策略研究进展[J].传染病信息,2017,06:321-326.
 ZHANG He-qian,CHANG Wen-xian,JIAO Yan-mei,et al.Research advance in the strategies for the eradication of HIV reservoir[J].Infectious Disease Information,2017,06:321-326.
点击复制

HIV 病毒库清除策略研究进展(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2017年06期
页码:
321-326
栏目:
导向与述评
出版日期:
2017-12-20

文章信息/Info

Title:
Research advance in the strategies for the eradication of HIV reservoir
作者:
张和倩常文仙焦艳梅张纪元王福生
233000,蚌埠医学院临床医学系(张和倩、常文仙);100039 北京,解放军第三○二医院感染性疾病诊疗与研究中心(焦艳梅、张纪元、王福生)
Author(s):
ZHANG He-qian CHANG Wen-xian JIAO Yan-mei ZHANG Ji-yuan* WANG Fu-sheng*
Department of Clinical Medicine, Bengbu Medical College, 233000, China
关键词:
HIV 病毒库免疫细胞清除策略
Keywords:
HIV reservoirs immunocytes eradication strategies
分类号:
R512.91
DOI:
10.3969/j.issn.1007-8134.2017.06.002
文献标识码:
A
摘要:
HIV 病毒库的长期存在是HIV 患者持续感染和难以彻底治愈的重要原因。目前以高效抗反转录病毒疗法为核心的治疗手段还难以将病毒库彻底清除。研究证实HIV 病毒库存在于多种类型的CD4+ T 细胞内,包括中心记忆CD4+ T 细胞、CCR4+CCR6+ 和CXCR3+CCR6+CD4+ T 细胞、干细胞样记忆CD4+ T 细胞、Vγ9Vδ2 T 细胞及近期证实的滤泡辅助性T 细胞等,而且有研究发现巨噬细胞、B 细胞中也可能存在病毒库。当前HIV 病毒库清除的策略主要有CCR5 基因缺陷造血干细胞移植,基因编辑及激活然后杀死等,但这些方法仍然不能有效清除HIV 病毒库。最新研究发现HIV 潜伏的CD4+ T 细胞表面CD32a 分子特异性高表达,这为病毒库的清除带来新的希望。本文旨在综述可能存在HIV 病毒库的免疫细胞及HIV 病毒库清除策略的研究进展。
Abstract:
The persistence of HIV reservoir is an important cause of persistent infection and difficult to cure in HIV patients. Itis difficult to completely remove the viral reservoir with HAART at present. Studies have confirmed that HIV reservoir exists in varioustypes of CD4+ T cells, including central memory CD4+ T cells, CCR4+CCR6+ and CXCR3+CCR6+ CD4+ T cells, stem cell like memoryCD4+ T cells, Vγ9Vδ2 T cells and recently confirmed Tfh cells. In addition, studies have also found that macrophages and B cells alsocouple with viral reservoir. Currently, HIV reservoir eradication strategies mainly include CCR5 gene defective hematopoietic stem celltransplantation, gene editing and activation then killing. These methods still can not effectively remove HIV reservoir. Recent studieshave shown the specifically high expression of CD32a molecules on the surface of HIV latent CD4+ T cells, which provides new markerfor the elimination of viral reservoir. We review the possible immunocytes with HIV reservoir and the research progress on the eradicationstrategies of HIV reservoir.

参考文献/References

[1] Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissuereservoirs and total body viral load in HIV-1 infection[J].Nature, 1997, 387(6629):183-188.
[2] Michaels SH, Clark R, Kissinger P. Declining morbidity andmortality among patients with advanced human immunodeficiencyvirus infection[J]. N Engl J Med, 1998, 339(6):405-406.
[3] Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenzplus zidovudine and lamivudine, efavirenz plus indinavir, andindinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team[J]. N Engl J Med, 1999,341(25):1865-1873.
[4] Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducibleHIV-1 latent reservoir during highly active antiretroviral therapy [J]. Proc Natl Acad Sci U S A, 1997, 94(24):13193-13197.
[5] Finzi D, Hermankova M, Pierson T, et al. Identification of areservoir for HIV-1 in patients on highly active antiretroviraltherapy[J]. Science, 1997, 278(5341):1295-1300.
[6] Kulkosky J, Nunnari G, Otero M, et al. Intensification andstimulation therapy for human immunodeficiency virus type1 reservoirs in infected persons receiving virally suppressivehighly active antiretroviral therapy[J]. J Infect Dis, 2002,186(10):1403-1411.
[7] Blankson JN, Persaud D, Siliciano RF. The challenge of viralreservoirs in HIV-1 infection[J]. Annu Rev Med, 2002, 53:557-593.
[8] Deeks SG, Lewin SR, Ross AL, et al. International AIDS Societyglobal scientific strategy: towards an HIV cure 2016[J]. NatMed, 2016, 22(8):839-850.
[9] Tyagi M, Pearson RJ, Karn J. Establishment of HIV latency inprimary CD4+ cells is due to epigenetic transcriptional silencingand P-TEFb restriction[J]. J Virol, 2010, 84(13):6425-6437.
[10] Strain MC, Lada SM, Luong T, et al. Highly precise measurementof HIV DNA by droplet digital PCR[J]. PLoS One, 2013,8(4):e55943.
[11] Bruner KM, Hosmane NN, Siliciano RF. Towards an HIV-1 cure:measuring the latent reservoir[J]. Trends Microbiol, 2015,23(4):192-203.
[12] Hindson BJ, Ness KD, Masquelier DA, et al. High-throughputdroplet digital PCR system for absolute quantitation of DNA copynumber[J]. Anal Chem, 2011, 83(22):8604-8610.
[13] Sanyal A, Mailliard RB, Rinaldo CR, et al. Novel assay reveals alarge, inducible, replication-competent HIV-1 reservoir in restingCD4+ T cells[J]. Nat Med, 2017, 23(7):885-889.
[14] Baxter AE, Niessl J, Fromentin R, et al. Multiparametriccharacterization of rare HIV-infected cells using an RNA-flowFISH technique[J]. Nat Protoc, 2017, 12(10):2029-2049.
[15] Riou C, Yassine-Diab B, Van Grevenynghe J, et al. Convergenceof TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells[J]. J ExpMed, 2007, 204(1):79-91.
[16] Chomont N, El-Far M, Ancuta P, et al. HIV reservoir sizeand persistence are driven by T cell survival and homeostaticproliferation[J]. Nature Medicine, 2009, 15(8):893-900.
[17] 杨鸿鸽,焦艳梅,王福生. 滤泡细胞毒性T 细胞参与HIV感染进程的研究进展[J]. 传染病信息,2016,29(6):321-323,344.
[18] Buzon MJ, Sun H, Li C, et al. HIV-1 persistence in CD4+ T cellswith stem cell-like properties[J]. Nat Med, 2014, 20(2):139-142.
[19] Gosselin A, Monteiro P, Chomont N, et al. Peripheral bloodCCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highlypermissive to HIV-1 infection[J]. J Immunol, 2010,184(3):1604-1616.
[20] Soriano-Sarabia N, Archin NM, Bateson R, et al. PeripheralVγ9Vδ2 T cells are a novel reservoir of latent HIV infection[J].PLoS Pathog, 2015, 11(10):e1005201.
[21] Farber DL, Yudanin NA, Restifo NP. Human memory T cells:generation, compartmentalization and homeostasis[J]. Nat RevImmunol, 2014, 14(1):24-35.
[22] Jaafoura S, de Goer DHM, Hernandez-Vargas EA, et al.Progressive contraction of the latent HIV reservoir around a coreof less-differentiated CD4(+) memory T Cells[J]. Nat Commun,2014, 5:5407.
[23] Perreau M, Savoye AL, De Crignis E, et al. Follicular helper T cellsserve as the major CD4 T cell compartment for HIV-1 infection,replication, and production[J]. J Exp Med, 2013, 210(1):143-156.
[24] Kohler SL, Pham MN, Folkvord JM, et al. Germinal center tfollicular helper cells are highly permissive to HIV-1 and altertheir phenotype during virus replication[J]. J Immunol, 2016,196(6):2711-2722.
[25] Honeycutt JB, Thayer WO, Baker CE, et al. HIV persistencein tissue macrophages of humanized myeloid-only mice duringantiretroviral therapy[J]. Nat Med, 2017, 23(5):638-643.
[26] Lahouassa H, Daddacha W, Hofmann H, et al. SAMHD1 restrictsthe replication of human immunodeficiency virus type 1 bydepleting the intracellular pool of deoxynucleoside triphosphates [J]. Nat Immunol, 2012, 13(3):223-228.
[27] Hrecka K, Hao C, Gierszewska M, et al. Vpx relieves inhibition ofHIV-1 infection of macrophages mediated by the SAMHD1 protein [J]. Nature, 2011, 474(7353):658-661.
[28] Micci L, Alvarez X, Iriele RI, et al. CD4 depletion in SIVinfectedmacaques results in macrophage and microglia infectionwith rapid turnover of infected cells[J]. PLoS Pathog, 2014,10(10):e1004467.
[29] Ortiz AM, Klatt NR, Li B, et al. Depletion of CD4(+) T cellsabrogates post-peak decline of viremia in SIV-infected rhesusmacaques[J]. J Clin Invest, 2011, 121(11):4433-4445.
[30] Calantone N, Wu F, Klase Z, et al. Tissue myeloid cells in SIVinfectedprimates acquire viral DNA through phagocytosis ofinfected T cells[J]. Immunity, 2014, 41(3):493-502.
[31] Arainga M, Edagwa B, Mosley RL, et al. A mature macrophageis a principal HIV-1 cellular reservoir in humanized miceafter treatment with long acting antiretroviral therapy[J].Retrovirology, 2017, 14(1):17.
[32] Castellano P, Prevedel L, Eugenin EA. HIV-infected macrophagesand microglia that survive acute infection become viral reservoirsby a mechanism involving Bim[J]. Sci Rep, 2017, 7(1):12866.
[33] Moir S, Lapointe R, Malaspina A, et al. CD40-Mediated inductionof CD4 and CXCR4 on B lymphocytes correlates with restrictedsusceptibility to human immunodeficiency virus type 1 infection:potential role of B lymphocytes as a viral reservoir[J]. J Virol,1999, 73(10):7972-7980.
[34] Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV byCCR5 Delta32/Delta32 stem-cell transplantation[J]. N Engl JMed, 2009, 360(7):692-698.
[35] Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIVinfection by CCR5Delta32/Delta32 stem cell transplantation[J].Blood, 2011,117(10):2791-2799.
[36] Marsden MD, Zack JA. Experimental approaches for eliminatinglatent HIV[J]. For Immunopathol Dis Therap, 2015, 6(1-2):91-99.
[37] Qin XF, An DS, Chen IS, et al. Inhibiting HIV-1 infection inhuman T cells by lentiviral-mediated delivery of small interferingRNA against CCR5[J]. Proc Natl Acad Sci U S A, 2003,100(1):183-188.
[38] Buehler DC, Marsden MD, Shen S, et al. Bioengineered vaults:self-assembling protein shell-lipophilic core nanoparticles for drugdelivery[J]. ACS Nano, 2014, 8(8):7723-7732.
[39] Kovochich M, Marsden MD, Zack JA. Activation of latentHIV using drug-loaded nanoparticles[J]. PLoS One, 2011,6(4):e18270.
[40] Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes alatent infection after acute infection of T cells in vitro[J]. EMBO J,2003, 22(8):1868-1877.
[41] Chun TW, Engel D, Mizell SB, et al. Effect of interleukin-2 on thepool of latently infected, resting CD4+ T cells in HIV-1-infectedpatients receiving highly active anti-retroviral therapy. [J] NatMed, 1999, 5(6):651-655.
[42] Archin NM, Eron JJ, Palmer S, et al. Valproic acid withoutintensified antiviral therapy has limited impact on persistent HIVinfection of resting CD4+ T cells[J]. AIDS, 2008, 22(10):1131-1135.
[43] Archin NM, Liberty AL, Kashuba AD, et al. Administration ofvorinostat disrupts HIV-1 latency in patients on antiretroviraltherapy[J]. Nature, 2012, 487(7408):482-485.
[44] Porichis F, Kaufmann DE. Role of PD-1 in HIV pathogenesis andas target for therapy[J]. Curr HIV/AIDS Rep, 2012, 9(1):81-90.
[45] Halper-Stromberg A, Lu CL, Klein F, et al. Broadly neutralizingantibodies and viral inducers decrease rebound from HIV-1 latentreservoirs in humanized mice[J]. Cell, 2014, 158(5):989-999.
[46] Marsden MD, Zack JA. Neutralizing the HIV reservoir[J]. Cell,2014, 158(5):971-972.
[47] Joseph A, Zheng JH, Follenzi A, et al. Lentiviral vectors encodinghuman immunodeficiency virus type 1 (HIV-1)-specific T-cellreceptor genes efficiently convert peripheral blood CD8 Tlymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity[J]. J Virol, 2008,82(6):3078-3089.
[48] Halper-Stromberg A, Lu CL, Klein F, et al. Broadly neutralizingantibodies and viral inducers decrease rebound from HIV-1 latentreservoirs in humanized mice[J]. Cell, 2014, 158(5):989-999.
[49] Descours B, Petitjean G, Lopez-Zaragoza JL, et al. CD32a is amarker of a CD4 T-cell HIV reservoir harbouring replicationcompetentproviruses[J]. Nature, 2017, 543(7646):564-567.
[50] Henrich TJ, Hanhauser E, Marty FM, et al. Antiretroviral-freeHIV-1 remission and viral rebound after allogeneic stem celltransplantation: report of 2 cases[J]. Ann Intern Med, 2014,161(5):319-327.
[51] Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1viremia after treatment cessation in an infant[J]. N Engl J Med,2013, 369(19):1828-1835.

备注/Memo

备注/Memo:
[基金项目] 首都特色基金(Z161100000516011)
[通信作者] 王福生,E-mail: fswang302@163.com;张纪元,E-mail:uniquezjy@163.com
更新日期/Last Update: 2017-12-20